Reuters logo
BRIEF-FDA grants priority review for Lilly's verzenio
October 12, 2017 / 11:02 AM / 2 months ago

BRIEF-FDA grants priority review for Lilly's verzenio

Oct 12 (Reuters) - Eli Lilly And Co:

* FDA grants priority review for potential new indication for Lilly’s verzenio (abemaciclib) as initial treatment of advanced breast cancer

* Eli Lilly And Co - ‍FDA’s goal is to take action within eight months of receiving an application, compared with standard review timeframe of 12 months​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below